Drugs, Diseases and the Managed Care Impact

(EDU-D2) AMCP Partner Session: Anemia of Chronic Kidney Disease: Dialysis and Non-Dialysis, What Does a Population-Based Decision Maker Need to Know?

Wednesday, October 12, 2022

1:00 PM – 2:15 PM ET

Location: Potomac C

ACPE UAN:N/A | Contact Hours: N/A | Activity Type: N/A

Faculty(s)

Stephen Brunton, MD, FAAFP, CDCES

Executive Director, Primary Care Metabolic Group
Associate Clinical Professor, Department of Pharmacy Practice Roseman University, Salt Lake City, Utah
Winnsboro, SC
Calvin Meaney, PharmD, BCPS

Clinical Associate Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Buffalo, NY

Moderator(s)

Tim S. Regan, BPharm, RPh, CPh

Vice President, Commercial Consulting
Xcenda, L.L.C., Carrollton, TX, USA
Carrollton, TX

This session is sponsored by GlaxoSmithKline and is not accredited for continuing pharmacy education contact hours.

Anemia of chronic kidney disease (CKD) is associated with poor clinical outcomes and increased healthcare resource utilization, including increased risk of hospitalization, cardiovascular complications, and mortality. Anemia of CKD is often untreated or undertreated, especially among non-dialysis patients.

This session will focus on the unmet need and economic burden for both non-dialysis and dialysis patients and the importance of earlier recognition and management. We will also review the role of the pharmacist in recognizing and managing anemia of CKD, with a particular emphasis on the non-dialysis setting.

Learning Objectives:

At the completion of this activity, participants should be able to:

Discuss the burden of untreated and undertreated anemia of CKD.
Review considerations of today’s standard of care and health-economic impact with current disease management paradigm.
Understand the role of the pharmacist for the anemia of CKD population.
Review the pathophysiology of anemia of CKD.